Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M7,734Revenue (TTM) $M2,177Net Margin (%)8.3Altman Z-Score4.7
Enterprise Value $M8,571EPS (TTM) $1.1Operating Margin %43.5Piotroski F-Score5
P/E(ttm)44.4Beneish M-Score-2.0Pre-tax Margin (%)11.9Higher ROA y-yN
Price/Book4.610-y EBITDA Growth Rate %25.8Quick Ratio0.8Cash flow > EarningsY
Price/Sales3.75-y EBITDA Growth Rate %17.5Current Ratio1.1Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %-42.2ROA % (ttm)5.8Higher Current Ratio y-yN
Dividend Yield %0.6PEG2.5ROE % (ttm)9.9Less Shares Outstanding y-yN
Payout Ratio %32.0Shares Outstanding M166ROIC % (ttm)27.3Gross Margin Increase y-yY

Gurus Latest Trades with RDY

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
RDYKen Fisher 2016-09-30 Add0.04%$43.61 - $54.45
($47.74)
$ 46.52-3%Add 8.99%5,696,909
RDYKen Fisher 2016-06-30 Add0.05%$41.9 - $51.23
($45.82)
$ 46.522%Add 9.46%5,227,024
RDYKen Fisher 2016-03-31 Add0.02%$41.22 - $48.86
($44.64)
$ 46.524%Add 6.00%4,775,345
RDYKen Fisher 2015-12-31 Reduce-0.06%$43.55 - $67.79
($54.62)
$ 46.52-15%Reduce -9.20%4,504,956
RDYKen Fisher 2015-09-30 Reduce-0.03%$55.59 - $67.73
($62.11)
$ 46.52-25%Reduce -4.55%4,961,550
RDYKen Fisher 2015-06-30 Reduce$51.8 - $60.54
($55.23)
$ 46.52-16%Reduce -0.34%5,198,254
RDYKen Fisher 2015-03-31 Add0.12%$47.73 - $57.1
($53.03)
$ 46.52-12%Add 25.58%5,216,225
RDYKen Fisher 2014-06-30 Add0.13%$38.67 - $46.08
($42.03)
$ 46.5211%Add 62.43%3,773,114
RDYKen Fisher 2014-03-31 Add0.08%$39.5 - $47.4
($43.29)
$ 46.527%Add 56.30%2,322,863
RDYKen Fisher 2013-06-30 Add0.04%$32.98 - $38.7
($36.5)
$ 46.5227%Add 48.42%1,283,605
RDYKen Fisher 2013-03-31 Add0.02%$32.03 - $36.57
($34.21)
$ 46.5236%Add 31.46%864,830
RDYKen Fisher 2012-09-30 Buy 0.05%$28.94 - $32.58
($30.12)
$ 46.5254%New holding604,555
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

RDY is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


RDY: Insider Buys/Sells

Click Here for All Insider Trades.

No Insider Trades Found!

Quarterly/Annual Reports about RDY:

    News about RDY:

    Articles On GuruFocus.com
    Growing Generic Drug Market a Good Opportuity for 2 India Firms May 30 2016 
    Ken Fisher Sells Shares of PMC Sierra, Alphabet During 4th Quarter Jan 15 2016 
    Emerging Market Stocks To Watch Out For Feb 17 2015 
    Should You Buy Actavis? Mar 18 2014 
    Dr. Reddy’s Laboratories: Should Continue to Gain Market Share in Lucrative Markets May 25 2012 
    5 Mid-Cap Healthcare Dividend Stocks with Perfect Earnings Growth Dec 05 2011 
    Abbott Laboratories and the “India Cure” for the Ailing Pharmaceutical Industry May 26 2010 

    More From Other Websites
    Do Hedge Funds Love Atmos Energy Corporation (ATO)? Dec 09 2016
    Dr. Reddy's Laboratories Announces the Launch of Nystatin and Triamcinolone Acetonide Cream, USP in... Dec 05 2016
    Dr. Reddy's Laboratories Announces the Launch of Nystatin and Triamcinolone Acetonide Cream, USP in... Dec 05 2016
    Arch Capital Group Ltd. (ACGL): Are Hedge Funds Right About This Stock? Dec 02 2016
    Is Newfield Exploration Co. (NFX) A Good Stock To Buy Right Now? Dec 01 2016
    How One Woman Silenced Her Twitter Trolls With a 78% Stock Rally Nov 30 2016
    Is Coty Inc (COTY) a Good Stock To Buy? Nov 29 2016
    Will Demonetization in India Impact Your Loan Burden? Nov 23 2016
    Dr. Reddy’s Labs Launches New Drug (RDY) Nov 14 2016
    Blog Coverage Dr. Reddy's Labs Launches Generic Osteoporosis Drug Tablets in the US Nov 14 2016
    Dr. Reddy's Laboratories announces the launch of Raloxifene HCl Tablets, USP in the U.S. Market Nov 11 2016
    Dr. Reddy's Laboratories Announces the Launch of Raloxifene HCl Tablets, USP in the U.S. Market Nov 11 2016
    Dr. Reddy's Laboratories Announces the Launch of Raloxifene HCl Tablets, USP in the U.S. Market Nov 11 2016
    ETF’s with exposure to Dr. Reddy’s Laboratories Ltd. : October 28, 2016 Oct 28 2016
    Dr. Reddy’s Laboratories Ltd. :RDY-US: Earnings Analysis: Q2, 2017 By the Numbers : October 27,... Oct 27 2016
    Dr. Reddy's Laboratories Announces New Strategic Deal with Gland Pharma in the U.S. Market Oct 26 2016
    Dr. Reddy's Laboratories Announces New Strategic Deal with Gland Pharma in the U.S. Market Oct 26 2016
    Dr. Reddy's (RDY) Earnings & Revenues Decline Y/Y in Q2 Oct 26 2016
    What Gives? Dr. Reddy's Shares Jump 6% Despite Earnings Miss Oct 25 2016
    Doctor Reddy's posts 2Q profit Oct 25 2016

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)